Biological psychiatry: on the relationship of schizophrenia and dopaminergic hyperactivity.
D000661:Amphetamine / Q000009:adverse effects / Q000037:antagonists & inhibitors; D000818:Animals; D002746:Chlorpromazine / Q000494:pharmacology; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000009:adverse effects*; D004777:Environment; D006213:Hallucinogens / Q000009:adverse effects; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007977:Levallorphan / Q000009:adverse effects; D009638:Norepinephrine / Q000009:adverse effects; D012559:Schizophrenia / Q000139:chemically induced*; D013315:Stress, Psychological; D013378:Substantia Nigra / Q000503:physiopathology; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000494:pharmacology
D006213:Hallucinogens; D014149:Tranquilizing Agents; D007977:Levallorphan; D000661:Amphetamine; D006220:Haloperidol; D002746:Chlorpromazine; D004298:Dopamine; D009638:Norepinephrine